{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:25:15Z","timestamp":1791001515258,"version":"4.1.0"},"reference-count":157,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["CEECIND\/00526\/2018"],"award-info":[{"award-number":["CEECIND\/00526\/2018"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/BTM\u2013SAL\/30071\/2017"],"award-info":[{"award-number":["PTDC\/BTM\u2013SAL\/30071\/2017"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/BIA\/04050\/2019"],"award-info":[{"award-number":["UID\/BIA\/04050\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04050\/2020"],"award-info":[{"award-number":["UIDB\/04050\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ejpb.2021.07.014","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T05:25:41Z","timestamp":1627449941000},"page":"89-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["Mesalazine and inflammatory bowel disease \u2013 From well-established therapies to progress beyond the state of the art"],"prefix":"10.1016","volume":"167","author":[{"given":"Pedro M.","family":"Veloso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Nobre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2021.07.014_b0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","article-title":"Inflammatory bowel disease: Pathogenesis","volume":"20","author":"Zhang","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0010","first-page":"1","article-title":"Incidence of inflammatory bowel disease by race and ethnicity in a population-based inception cohort from 1970 through 2010","volume":"1","author":"Harmsen","year":"2019","journal-title":"Therap. Adv. Gastroenterol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0015","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3109\/00365521.2015.1014407","article-title":"The epidemiology of inflammatory bowel disease","volume":"50","author":"Burisch","year":"2015","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0020","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.ejpb.2021.07.014_b0025","doi-asserted-by":"crossref","first-page":"444 LP","DOI":"10.1136\/gut.2004.051797","article-title":"The complicated path to true causes of disease: role of nuclear factor \u03baB in inflammatory bowel disease","volume":"54","author":"Schreiber","year":"2005","journal-title":"Gut."},{"key":"10.1016\/j.ejpb.2021.07.014_b0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11882-015-0562-9","article-title":"Immune Responses to Intestinal Microbes in Inflammatory Bowel Diseases","volume":"15","author":"Hansen","year":"2015","journal-title":"Curr. Allergy Asthma Rep."},{"key":"10.1016\/j.ejpb.2021.07.014_b0035","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/1871528113666140118202140","article-title":"Microbiota Regulation of Inflammatory Bowel Disease","volume":"13","author":"Evans-Marin","year":"2014","journal-title":"Inflamm. Allergy - Drug Targets."},{"key":"10.1016\/j.ejpb.2021.07.014_b0040","doi-asserted-by":"crossref","first-page":"E1394","DOI":"10.1503\/cmaj.190976","article-title":"Life expectancy and health-adjusted life expectancy in people with inflammatory bowel disease","volume":"192","author":"Ellen Kuenzig","year":"2020","journal-title":"Cmaj."},{"key":"10.1016\/j.ejpb.2021.07.014_b0045","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/jgh.13596","article-title":"Overall and Cause-specific Mortality in Korean Patients with Inflammatory Bowel Disease: A Hospital-based Cohort Study","volume":"32","author":"Lee","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0050","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1097\/MIB.0000000000000173","article-title":"Inflammatory Bowel Disease Cause-specific Mortality: A Primer for Clinicians","volume":"20","author":"Kassam","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejpb.2021.07.014_b0055","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1080\/003655200453610","article-title":"Disease Outcome in Inflammatory Bowel Disease: Mortality, Morbidity and Therapeutic Management of a 796-Person Inception Cohort in the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD)","volume":"35","author":"Witte","year":"2000","journal-title":"Scand. J. Gastroenterol."},{"issue":"2020","key":"10.1016\/j.ejpb.2021.07.014_b0060","first-page":"17","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study","volume":"5","author":"Alatab","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0065","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/ibd\/izz038","article-title":"The Inflammatory Bowel Disease Symptom Inventory: A Patient-report Scale for Research and Clinical Application","volume":"25","author":"Sexton","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejpb.2021.07.014_b0070","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.pop.2017.07.010","article-title":"An Update on Inflammatory Bowel Disease","volume":"44","author":"Sairenji","year":"2017","journal-title":"Prim. Care Clin. Off. Pract."},{"key":"10.1016\/j.ejpb.2021.07.014_b0075","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3109\/00365529709011218","article-title":"Inflammatory Bowel Disease: A Study of the Association between Anxiety and Depression, Physical Morbidity, and Nutritional Status","volume":"32","author":"Addolorato","year":"1997","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0080","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1744-6155.2011.00292.x","article-title":"Illness-specific anxiety: Implications for functioning and utilization of medical services in adolescents with inflammatory bowel disease","volume":"16","author":"Reigada","year":"2011","journal-title":"J. Spec. Pedriatric Nurs."},{"key":"10.1016\/j.ejpb.2021.07.014_b0085","first-page":"237","article-title":"Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease","author":"Williams","year":"2015","journal-title":"Therap. Adv. Gastroenterol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0090","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.3748\/wjg.v20.i12.3255","article-title":"Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease","volume":"20","author":"Xu","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0095","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1590-8658(01)80108-0","article-title":"Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effecs","volume":"33","author":"Di Paolo","year":"2001","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.ejpb.2021.07.014_b0100","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1046\/j.1365-2036.2001.01060.x","article-title":"Review article: the limitations of corticosteroid therapy in Crohn\u2019s disease","volume":"15","author":"Rutgeerts","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2021.07.014_b0105","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"Vande Casteele, JAK\u2013STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0110","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/apt.15097","article-title":"Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease","volume":"49","author":"Shivaji","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2021.07.014_b0115","article-title":"Traditional corticosteroids for induction of remission in Crohn\u2019s disease (Review)","author":"Ei","year":"2008","journal-title":"Chochrane Database Syst. Rev."},{"key":"10.1016\/j.ejpb.2021.07.014_b0120","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.dld.2017.01.161","article-title":"Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease","volume":"49","author":"Gionchetti","year":"2017","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.ejpb.2021.07.014_b0125","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/ecco-jcc\/jjaa053","article-title":"The historical role and contemporary use of corticosteroids in inflammatory bowel disease","volume":"14","author":"Dorrington","year":"2020","journal-title":"J. Crohn\u2019s Colitis."},{"key":"10.1016\/j.ejpb.2021.07.014_b0130","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1159\/000338128","article-title":"Second-Generation Corticosteroids for the Treatment of Crohn\u2019s Disease and Ulcerative Colitis: More Effective and Less Side Effects?","volume":"30","author":"De Cassan","year":"2012","journal-title":"Dig. Dis."},{"key":"10.1016\/j.ejpb.2021.07.014_b0135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.dld.2011.09.015","article-title":"The use of methotrexate for treatment of inflammatory bowel disease in clinical practice","volume":"44","author":"Saibeni","year":"2012","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.ejpb.2021.07.014_b0140","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1046\/j.1365-2036.2001.01102.x","article-title":"Review article: the treatment of in inflammatory bowel disease with 6-mercaptopurine or azathioprine","volume":"15","author":"Nielsen","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2021.07.014_b0145","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/ajg.2011.64","article-title":"Efficacy of Immunosuppressive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis","volume":"106","author":"Khan","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0150","article-title":"Azathioprine in inflammatory bowel disease: improved molecular insights and resulting clinical implications","volume":"23\u201334","author":"Profile","year":"2008","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0155","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/MCG.0000000000000696","article-title":"Biological Therapy in Pediatric Inflammatory Bowel Disease: A Systematic Review","volume":"51","author":"Corica","year":"2017","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0160","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/apt.14030","article-title":"Systematic review with meta-analysis: Comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn\u2019s disease and ulcerative colitis controlled trials","volume":"45","author":"Cholapranee","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2021.07.014_b0165","doi-asserted-by":"crossref","unstructured":"A.C. Moss, Mechanism of Action and Pharmacokinetics of Biologics, in: A. Cheifetz, J. Feuerstein (Eds.), Treat. Inflamm. Bowel Dis. With Biol., Springer, Cham, 2017, pp. 1\u201311. http:\/\/dx.doi.10.1007\/978-3-319-60276-9_1.","DOI":"10.1007\/978-3-319-60276-9_1"},{"key":"10.1016\/j.ejpb.2021.07.014_b0170","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/cpt.791","article-title":"Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease","volume":"102","author":"Hindryckx","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2021.07.014_b0175","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s10620-018-5329-4","article-title":"Retention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in Italy","volume":"64","author":"Sartini","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejpb.2021.07.014_b0180","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2036.2006.03069.x","article-title":"Review article: mode of action and delivery of 5-aminosalicylic acid \u2013 new evidence","volume":"24","author":"Desreumaux","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2021.07.014_b0185","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1007\/s10620-018-5181-6","article-title":"Physicians\u2019 Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn\u2019s Disease","volume":"63","author":"Ma","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejpb.2021.07.014_b0190","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/ibd\/izaa127","article-title":"Trends of 5-Aminosalicylate Medication Use in Patients With Crohn Disease","volume":"27","author":"Noureldin","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejpb.2021.07.014_b0195","first-page":"577","article-title":"Salazopyrin, a new sulfanilamide preparation","volume":"110","author":"Results","year":"1942","journal-title":"Acta Med. Scand."},{"key":"10.1016\/j.ejpb.2021.07.014_b0200","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3109\/00365521.2015.1018937","article-title":"5-Aminosalicylic acid, a specific drug for ulcerative colitis","volume":"50","author":"Hauso","year":"2015","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0205","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1517\/17425247.4.5.547","article-title":"Azo compounds in colon-specific drug delivery","volume":"4","author":"Roldo","year":"2007","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2021.07.014_b0210","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.0269-2813.2004.01827.x","article-title":"Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis","volume":"19","author":"Jr","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2021.07.014_b0215","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/ajg.2011.67","article-title":"Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0220","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1053\/j.gastro.2018.12.008","article-title":"AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis","volume":"156","author":"Singh","year":"2019","journal-title":"Gastroenterology."},{"key":"10.1016\/j.ejpb.2021.07.014_b0225","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1023\/A:1018909527659","article-title":"Evaluation of the Physicochemical Properties and Dissolution Characteristics of Mesalamine: Relevance of Controlled Intestinal Drug Delivery","volume":"10","author":"French","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2021.07.014_b0230","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/poc.1489","article-title":"The photophysics of salicylic acid derivatives in aqueous solution","volume":"22","author":"Pozdnyakov","year":"2009","journal-title":"J. Phys. Org. Chem."},{"key":"10.1016\/j.ejpb.2021.07.014_b0235","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40262-018-0676-z","article-title":"Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis","volume":"58","author":"Berends","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2021.07.014_b0240","doi-asserted-by":"crossref","unstructured":"M.S. Moyer, 5-Aminosalicylate Therapy, in: P. Mamula, J.E. Markowitz, R.N. Baldassano (Eds.), Pediatr. Inflamm. Bowel Dis., Springer US, Boston, MA, 2008, pp. 317\u2013328. http:\/\/dx.doi.10.1007\/978-0-387-73481-1_24.","DOI":"10.1007\/978-0-387-73481-1_24"},{"key":"10.1016\/j.ejpb.2021.07.014_b0245","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0090-9556(24)15210-5","article-title":"Intestinal Metabolism and Transport of 5-aminosalicylate","volume":"27","author":"Zhou","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejpb.2021.07.014_b0250","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/ecp.12.2","article-title":"Mesalamine in the treatment and maintenance of remission of ulcerative colitis","volume":"5","author":"Ham","year":"2012","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0255","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008870.pub2","article-title":"Aminosalicylates for induction of remission or response in Crohn\u2019s disease (Review)","author":"Lim","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejpb.2021.07.014_b0260","article-title":"Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn\u2019s disease (Review)","author":"Gjuladin-Hellon","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejpb.2021.07.014_b0265","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/MIB.0000000000000823","article-title":"Importance of the Evaluation of N-Acetyltransferase Enzyme Activity Prior to 5-Aminosalicylic Acid Medication for Ulcerative Colitis","volume":"22","author":"Matthis","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.ejpb.2021.07.014_b0270","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1046\/j.1365-2125.2000.00164.x","article-title":"Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters","volume":"49","author":"Hussain","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0275","doi-asserted-by":"crossref","first-page":"17972","DOI":"10.3390\/ijms140917972","article-title":"Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Mesalazine in the Chemoprevention of Colorectal Cancer","volume":"14","author":"Stolfi","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2021.07.014_b0280","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2036.18.s2.1.x","article-title":"Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease","volume":"18","author":"Allgayer","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2021.07.014_b0285","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2624941","article-title":"Nuclear Receptors in the Pathogenesis and Management of Inflammatory Bowel Disease","volume":"2019","author":"Ning","year":"2019","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.ejpb.2021.07.014_b0290","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001651","article-title":"The Nuclear Factor NF-\u03baB Pathway In Inflammation","volume":"1","author":"Lawrence","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0295","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/MCG.0000000000000864","article-title":"The Use of 5-Aminosalicylic Acid in Children and Adolescents With Inflammatory Bowel Disease","volume":"51","author":"Sokollik","year":"2018","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0300","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004115.pub2","article-title":"Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis (Review)","author":"Marshall","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejpb.2021.07.014_b0305","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1365-2036.2011.04599.x","article-title":"Review article: remission rates achievable by current therapies for inflammatory bowel disease","volume":"33","author":"Peyrin-Biroulet","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2021.07.014_b0310","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1093\/carcin\/bgt245","article-title":"The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPAR\u03b3","volume":"34","author":"Rousseaux","year":"2013","journal-title":"Carginogenesis."},{"key":"10.1016\/j.ejpb.2021.07.014_b0315","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.dld.2008.09.003","article-title":"Inhibition of cell proliferation and invasion in a human colon cancer cell line by 5-aminosalicylic acid","volume":"41","author":"Kim","year":"2009","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.ejpb.2021.07.014_b0320","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.18632\/oncotarget.13715","article-title":"Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis","volume":"8","author":"Qiu","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.ejpb.2021.07.014_b0325","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1007\/s10620-018-5378-8","article-title":"Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis","volume":"64","author":"Bajpai","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejpb.2021.07.014_b0330","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.gtc.2020.07.002","article-title":"Mesalamine in the Initial Therapy of Ulcerative Colitis","volume":"49","author":"Chibbar","year":"2020","journal-title":"Gastroenterol. Clin. North Am."},{"key":"10.1016\/j.ejpb.2021.07.014_b0335","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1136\/gutjnl-2014-307595","article-title":"The stomach in health and disease","volume":"64","author":"Hunt","year":"2015","journal-title":"Gut."},{"key":"10.1016\/j.ejpb.2021.07.014_b0340","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.48.4.571","article-title":"Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs","volume":"48","author":"Nugent","year":"2001","journal-title":"Gut."},{"key":"10.1016\/j.ejpb.2021.07.014_b0345","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1517\/17425247.5.5.483","article-title":"Target-specific drug release to the colon","volume":"5","author":"Jain","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2021.07.014_b0350","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1517\/17425247.2013.736962","article-title":"Eudragit: a technology evaluation","volume":"10","author":"Thakral","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2021.07.014_b0355","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.gtc.2010.08.011","article-title":"Clinical Pharmacology of 5-ASA Compounds in Inflammatory Bowel Disease","volume":"39","author":"Sonu","year":"2010","journal-title":"Gastroenterol. Clin. North Am."},{"key":"10.1016\/j.ejpb.2021.07.014_b0360","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/1756283X17709974","article-title":"MMX\u00ae technology and its applications in gastrointestinal diseases","volume":"10","author":"Nardelli","year":"2017","journal-title":"Therap. Adv. Gastroenterol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0365","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.2165\/00003495-200767170-00010","article-title":"Delayed-Release Multi Matrix System (MMX TM) Mesalazine In Ulcerative Colitis","volume":"67","author":"McCormack","year":"2007","journal-title":"Drugs."},{"key":"10.1016\/j.ejpb.2021.07.014_b0370","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2036.1992.tb00269.x","article-title":"A pharmacokinetic study of sulphasalazine and two new formulations of mesalazine","volume":"6","author":"Swift","year":"1992","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2021.07.014_b0375","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/j.1365-2036.2004.01964.x","article-title":"Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers","volume":"19","author":"Sandborn","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2021.07.014_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119372","article-title":"OPTICORETM, an innovative and accurate colonic targeting technology","volume":"583","author":"Varum","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2021.07.014_b0385","first-page":"292","article-title":"Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis","volume":"46","author":"D\u2019Haens","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2021.07.014_b0390","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3109\/03639045.2011.560156","article-title":"Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease","volume":"37","author":"Bautzov\u00e1","year":"2011","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2021.07.014_b0395","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2165\/00003495-200868080-00006","article-title":"Improving Delivery of Aminosalicylates in Ulcerative Colitis: Effect on Patient Outcomes","volume":"68","author":"Fernandez-Becker","year":"2008","journal-title":"Drugs."},{"key":"10.1016\/j.ejpb.2021.07.014_b0400","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1586\/eci.10.22","article-title":"Once-daily mesalamine granules for ulcerative colitis","volume":"6","author":"Lawlor","year":"2010","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0405","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/j.gastro.2009.12.054","article-title":"Once-Daily Dosing of Delayed-Release Oral Mesalamine (400-mg Tablet) Is as Effective as Twice-Daily Dosing for Maintenance of Remission of Ulcerative Colitis","volume":"138","author":"Sandborn","year":"2010","journal-title":"Gastroenterology."},{"key":"10.1016\/j.ejpb.2021.07.014_b0410","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1517\/14656566.9.6.1049","article-title":"MMX mesalamine: a novel 5-aminosalicylate formulation for the treatment of ulcerative colitis","volume":"9","author":"Hu","year":"2008","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejpb.2021.07.014_b0415","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1586\/17474124.2.3.299","article-title":"Mesalamine with MMX TM technology for the treatment of ulcerative colitis","volume":"2","author":"Schreiber","year":"2008","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/6928710","article-title":"Oral 5-Aminosalicylate, Mesalamine Suppository and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications","volume":"2016","author":"Richter","year":"2016","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0425","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000341947","article-title":"Topical Therapies in Inflammatory Bowel Disease","volume":"86","author":"Frei","year":"2012","journal-title":"Digestion."},{"key":"10.1016\/j.ejpb.2021.07.014_b0430","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/00365529009091913","article-title":"Role of Rectal Formulations: Suppositories","volume":"25","author":"Williams","year":"1990","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0435","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.addr.2004.08.008","article-title":"Mesalamine delivery systems: do they really make much difference?","volume":"57","author":"Qureshi","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2021.07.014_b0440","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2036.2006.03059.x","article-title":"Review article: aminosalicylates for distal colitis","volume":"24","author":"Gionchetti","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2021.07.014_b0445","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/00004836-198808000-00012","article-title":"5-Aminosalicylic Acid as Enemas Or Suppositories in Distal Ulcerative Colitis?","volume":"10","author":"Campieri","year":"1988","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0450","doi-asserted-by":"crossref","first-page":"338","DOI":"10.2174\/156720112801323062","article-title":"Foam Preparations for the Treatment of Ulcerative Colitis Distribution of Rectal Agents","volume":"9","author":"Loew","year":"2012","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ejpb.2021.07.014_b0455","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1572-0241.2000.01679.x","article-title":"Comparative, Open, Randomized Trial of the Efficacy and Tolerance of Slow-Release 5-ASA Suppositories Once Daily Versus Conventional 5-ASA Suppositories Twice Daily in the Treatment of Active Cryptogenic Proctitis","volume":"95","author":"Marteau","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0460","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1046\/j.1365-2036.1997.00259.x","article-title":"Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis","volume":"11","author":"Gionchetti","year":"1997","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2021.07.014_b0465","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/j.1365-2036.2011.04619.x","article-title":"Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis","volume":"33","author":"Harris","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2021.07.014_b0470","doi-asserted-by":"crossref","unstructured":"B. co. staff, Medical gallery of Blausen Medical 2014, WikiJournal Med. 1 (2014). http:\/\/dx.doi.10.15347\/wjm\/2014.010.","DOI":"10.15347\/wjm\/2014.010"},{"key":"10.1016\/j.ejpb.2021.07.014_b0475","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.crohns.2013.03.005","article-title":"Topical therapy is underused in patients with ulcerative colitis","volume":"8","author":"Seibold","year":"2014","journal-title":"J. Crohn\u2019s Colitis."},{"key":"10.1016\/j.ejpb.2021.07.014_b0480","article-title":"Modern use of 5-aminosalicylic acid compounds for ulcerative colitis","author":"Le Berre","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ejpb.2021.07.014_b0485","first-page":"1117","article-title":"Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: Selective targeting to diseased versus healthy tissue, Nanomedicine Nanotechnology","volume":"11","author":"Hua","year":"2015","journal-title":"Biol. Med."},{"key":"10.1016\/j.ejpb.2021.07.014_b0490","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jconrel.2012.01.028","article-title":"Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa","volume":"161","author":"Collnot","year":"2012","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2021.07.014_b0495","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1016\/j.biomaterials.2008.08.009","article-title":"The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis","volume":"29","author":"Moulari","year":"2008","journal-title":"Biomaterials."},{"key":"10.1016\/j.ejpb.2021.07.014_b0500","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3892\/mmr.2017.6153","article-title":"5-ASA-loaded SiO2 nanoparticles-a novel drug delivery system targeting therapy on ulcerative colitis in mice","volume":"15","author":"Tang","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejpb.2021.07.014_b0505","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1021\/acs.molpharmaceut.9b00041","article-title":"Double Drug Delivery Using Capped Mesoporous Silica Microparticles for the Effective Treatment of Inflammatory Bowel Disease","volume":"16","author":"Teruel","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2021.07.014_b0510","doi-asserted-by":"crossref","first-page":"9210","DOI":"10.1016\/j.biomaterials.2013.08.035","article-title":"Diatom silica microparticles for sustained release and permeation enhancement following oral delivery of prednisone and mesalamine","volume":"34","author":"Zhang","year":"2013","journal-title":"Biomaterials."},{"key":"10.1016\/j.ejpb.2021.07.014_b0515","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejps.2015.10.003","article-title":"A pH dependent delivery of mesalazine from polymer coated and drug-loaded SBA-16 systems","volume":"81","author":"Trendafilova","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2021.07.014_b0520","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijpharm.2007.05.028","article-title":"Colon-specific delivery of 5-aminosalicylic acid from chitosan-Ca-alginate microparticles","volume":"342","author":"Mladenovska","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2021.07.014_b0525","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.colsurfb.2016.05.038","article-title":"Mucoadhesive microparticulates based on polysaccharide for target dual drug delivery of 5-aminosalicylic acid and curcumin to inflamed colon","volume":"145","author":"Duan","year":"2016","journal-title":"Colloids Surfaces B Biointerfaces."},{"key":"10.1016\/j.ejpb.2021.07.014_b0530","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.carbpol.2018.06.106","article-title":"Mesalazine\/hydroxypropyl-\u03b2-cyclodextrin\/chitosan nanoparticles with sustained release and enhanced anti-inflammation activity","volume":"198","author":"Tang","year":"2018","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2021.07.014_b0535","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ijbiomac.2010.10.005","article-title":"Synthesis and in vitro evaluation of carboxymethyl starch\u2013chitosan nanoparticles as drug delivery system to the colon","volume":"48","author":"Saboktakin","year":"2011","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0540","article-title":"Chitosan-5-aminosalicylic acid conjugates for colon-specific drug delivery: Methods of preparation and in vitro evaluations","volume":"57","author":"Nalinbenjapun","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.reactfunctpolym.2020.104520","article-title":"Functionalization of ginger derived nanoparticles with chitosan to design drug delivery system for controlled release of 5-amino salicylic acid (5-ASA) in treatment of inflammatory bowel diseases: An in vitro study","volume":"149","author":"Markam","year":"2020","journal-title":"React. Funct. Polym."},{"key":"10.1016\/j.ejpb.2021.07.014_b0550","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.carbpol.2019.02.049","article-title":"Improvement of the therapeutic treatment of inflammatory bowel diseases following rectal administration of mesalazine-loaded chitosan microparticles vs Asamax\u00ae","volume":"212","author":"Palma","year":"2019","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2021.07.014_b0555","doi-asserted-by":"crossref","unstructured":"R. Wouters, Inulin, in: Food Stabilisers, Thick. Gelling Agents, John Wiley & Sons, Ltd, 2009, pp. 180\u2013197. http:\/\/dx.doi.10.1002\/9781444314724.ch10.","DOI":"10.1002\/9781444314724.ch10"},{"key":"10.1016\/j.ejpb.2021.07.014_b0560","series-title":"Ind. Biorefineries White Biotechnol","first-page":"653","article-title":"Chapter 19 - Production and Extraction of Polysaccharides and Oligosaccharides and Their Use as New Food Additives","author":"Nobre","year":"2015"},{"key":"10.1016\/j.ejpb.2021.07.014_b0565","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.carbpol.2018.07.015","article-title":"Degradation studies of modified inulin as potential encapsulation material for colon targeting and release of mesalamine","volume":"199","author":"Walz","year":"2018","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2021.07.014_b0570","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijpharm.2009.08.030","article-title":"Carboxymethyl high amylose starch as excipient for controlled drug release: Mechanistic study and the influence of degree of substitution","volume":"382","author":"Lemieux","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2021.07.014_b0575","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.colsurfb.2013.12.007","article-title":"Fabrication and evaluation of the novel reduction-sensitive starch nanoparticles for controlled drug release","volume":"115","author":"Yang","year":"2014","journal-title":"Colloids Surfaces B Biointerfaces."},{"key":"10.1016\/j.ejpb.2021.07.014_b0580","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.carbpol.2018.03.025","article-title":"Starch film-coated microparticles for oral colon-specific drug delivery","volume":"191","author":"Chen","year":"2018","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2021.07.014_b0585","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ijbiomac.2018.01.184","article-title":"Carboxymethyl cellulose-rosin gum hybrid nanoparticles: An efficient drug carrier","volume":"112","author":"Singh","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0590","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/masy.201251010","article-title":"Nanoparticles Synthesis from Corn Cob (Xylan) and Their Potential Application as Colon-Specific Drug Carrier","volume":"320","author":"Kumar","year":"2012","journal-title":"Macromol. Symp."},{"key":"10.1016\/j.ejpb.2021.07.014_b0595","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3109\/02652048.2013.788087","article-title":"Producing xylan\/Eudragit\u00ae S100-based microparticles by chemical and physico-mechanical approaches as carriers for 5-aminosalicylic acid","volume":"30","author":"Silva","year":"2013","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejpb.2021.07.014_b0600","article-title":"Lipid-polymer nano core-shell type hybrid system for colon specific drug delivery","volume":"63","author":"Wang","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0605","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ijbiomac.2017.08.085","article-title":"Synthesis of Aloevera\/Acrylonitrile based Nanoparticles for targeted drug delivery of 5-Aminosalicylic acid","volume":"106","author":"Malviya","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0610","doi-asserted-by":"crossref","first-page":"6454","DOI":"10.3390\/ijms13056454","article-title":"A Novel Preparation Method for 5-Aminosalicylic Acid Loaded Eudragit S100 Nanoparticles","volume":"13","author":"Hu","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2021.07.014_b0615","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jconrel.2007.08.008","article-title":"5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease","volume":"123","author":"Pertuit","year":"2007","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2021.07.014_b0620","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/jbm.a.36305","article-title":"Intestinal Organoids Containing PLGA Nanoparticles for the Treatment of Inflammatory Bowel Diseases","volume":"106","author":"Davoudi","year":"2018","journal-title":"J. Biomed. Mater. Res. Part A."},{"key":"10.1016\/j.ejpb.2021.07.014_b0625","doi-asserted-by":"crossref","first-page":"s46","DOI":"10.5530\/ijper.51.2s.49","article-title":"Optimization and in-vitro Evaluation of Poly (lactic acid)\/Mesalazine Microspheres as Drug Carriers","volume":"51","author":"Banabid","year":"2017","journal-title":"Indian J. Pharm. Educ. Res."},{"key":"10.1016\/j.ejpb.2021.07.014_b0630","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijpharm.2019.01.002","article-title":"Interpolymer complexes of carbopol \u00ae 971 and poly(2-ethyl-2-oxazoline): Physicochemical studies of complexation and formulations for oral drug delivery","volume":"558","author":"Moustafine","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2021.07.014_b0635","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S1773-2247(08)50062-1","article-title":"Targeted delivery of 5-ASA to colon using chitosan hydrogel microspheres","volume":"18","author":"Jain","year":"2008","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0640","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.carbpol.2010.02.034","article-title":"Synthesis and characterization of superparamagnetic chitosan\u2013dextran sulfate hydrogels as nano carriers for colon-specific drug delivery","volume":"81","author":"Saboktakin","year":"2010","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2021.07.014_b0645","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.carbpol.2010.04.086","article-title":"Study of the sigmoidal swelling kinetics of carboxymethylchitosan-g-poly (acrylic acid) hydrogels intended for colon-specific drug delivery","volume":"82","author":"Tu","year":"2010","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2021.07.014_b0650","first-page":"4955","article-title":"Synthesis and Characterization of Chitosan Hydrogels Containing 5-Aminosalicylic Acid Nanopendents for Colon: Specific Drug Delivery","volume":"99","author":"Saboktakin","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2021.07.014_b0655","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1163\/092050611X601720","article-title":"In Vitro Degradation and Drug-Release Properties of Water-Soluble Chitosan Cross-Linked Oxidized Sodium Alginate Core-Shell Microgels","volume":"23","author":"Chen","year":"2012","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"10.1016\/j.ejpb.2021.07.014_b0660","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijbiomac.2012.09.018","article-title":"International Journal of Biological Macromolecules Controlled release of 5-aminosalicylicacid from chitosan based pH and temperature sensitive hydrogels","volume":"52","author":"Bostan","year":"2013","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0665","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijpharm.2015.06.026","article-title":"Designing a biocompatible hydrogel for the delivery of mesalamine","volume":"491","author":"Neufeld","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2021.07.014_b0670","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/03639040601150278","article-title":"Synthesis of Chemically Cross-Linked Hydroxypropyl Methyl Cellulose Hydrogels and their Application in Controlled Release of 5-Amino Salicylic Acid","volume":"33","author":"Davaran","year":"2007","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2021.07.014_b0675","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.colsurfb.2013.04.033","article-title":"Hydroxypropyl methyl cellulose grafted with polyacrylamide: Application in controlled release of 5-amino salicylic acid","volume":"110","author":"Das","year":"2013","journal-title":"Colloids Surfaces B Biointerfaces."},{"key":"10.1016\/j.ejpb.2021.07.014_b0680","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ijbiomac.2015.03.015","article-title":"Modified hydroxypropyl methyl cellulose: Efficient matrix for controlled release of 5-amino salicylic acid","volume":"77","author":"Das","year":"2015","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0685","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.1016\/j.polymer.2005.05.041","article-title":"Synthesis and properties of degradable hydrogels of konjac glucomannan grafted acrylic acid for colon-specific drug delivery","volume":"46","author":"Chen","year":"2005","journal-title":"Polymer (Guildf)."},{"key":"10.1016\/j.ejpb.2021.07.014_b0690","doi-asserted-by":"crossref","first-page":"45327","DOI":"10.1002\/app.45327","article-title":"The effects of graphene oxide on the properties and drug delivery of konjac glucomannan hydrogel","volume":"134","author":"Yuan","year":"2017","journal-title":"J. Appl. Polym. Sci."},{"key":"10.1016\/j.ejpb.2021.07.014_b0695","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ijbiomac.2017.03.167","article-title":"Pectin-chitosan physical hydrogels as potential drug delivery vehicles","volume":"101","author":"Neufeld","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0700","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10847-018-0863-4","article-title":"Control releasing 5-aminosalicylic acid using pH-sensitive hydrogel with novel albumin cross-linker","volume":"92","author":"Habibi","year":"2018","journal-title":"J. Incl. Phenom. Macrocycl. Chem."},{"key":"10.1016\/j.ejpb.2021.07.014_b0705","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.carbpol.2013.01.004","article-title":"Aluminium and radiation cross-linked carboxymethyl sago pulp beads for colon targeted delivery","volume":"94","author":"Thenapakiam","year":"2013","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2021.07.014_b0710","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s13233-017-5150-5","article-title":"pH-Sensitive Mesalazine Carrier for Colon-Targeted Drug Delivery: A Two-Fold Composition of Mesalazine with a Clay and Alginate","volume":"25","author":"Hong","year":"2017","journal-title":"Macromol. Res."},{"key":"10.1016\/j.ejpb.2021.07.014_b0715","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.carbpol.2017.01.097","article-title":"Novel levan and pNIPA temperature sensitive hydrogels for 5-ASA controlled release","volume":"165","author":"Osman","year":"2017","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2021.07.014_b0720","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.carbpol.2018.08.053","article-title":"Beta-Glucan based temperature responsive hydrogels for 5-ASA delivery","volume":"201","author":"Eyigor","year":"2018","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2021.07.014_b0725","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/BF02973887","article-title":"Drug Release from the Enzyme-Degradable and pH-Sensitive Hydrogel Composed of Glycidyl Methacrylate Dextran and Poly(acrylic acid)","volume":"28","author":"Kim","year":"2005","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.ejpb.2021.07.014_b0730","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/pat.1018","article-title":"Synthesis, characterization and evaluation of semi-IPN hydrogels consisted of poly(methacrylic acid) and guar gum for colon-specific drug delivery","volume":"19","author":"Li","year":"2008","journal-title":"Polym. Adv. Technol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0735","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1515\/epoly.2008.8.1.1831","article-title":"Synthesis, characterization and evaluation of poly[glucose acrylate-methacrylic acid] hydrogels for colon-specific drug delivery","volume":"8","author":"Mahkam","year":"2008","journal-title":"E-Polymers."},{"key":"10.1016\/j.ejpb.2021.07.014_b0740","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1039\/c2py20086d","article-title":"Biodegradable, pH-sensitive P(CL-Pluronic-CL-co-MAA-MEG) hydrogel for 5-aminosalicylic acid delivery","volume":"3","author":"Wang","year":"2012","journal-title":"Polym. Chem."},{"key":"10.1016\/j.ejpb.2021.07.014_b0745","first-page":"1926","article-title":"Wang, Novel pH-sensitive hydrogels for 5-aminosalicylic acid colon targeting delivery: in vivo study with ulcerative colitis targeting therapy in mice","volume":"23","author":"Bai","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2021.07.014_b0750","doi-asserted-by":"crossref","first-page":"13749","DOI":"10.1021\/jp8041389","article-title":"Enzyme-Catalyzed Formation and Structure Characteristics of A Protein-Based Hydrogel","volume":"112","author":"Song","year":"2008","journal-title":"J. Phys. Chem. B."},{"key":"10.1016\/j.ejpb.2021.07.014_b0755","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1039\/D1TB00499A","article-title":"Thermosensitive polymer hydrogel as a physical shield on colonic mucosa for colitis treatment","volume":"9","author":"Guo","year":"2021","journal-title":"J. Mater. Chem. B."},{"key":"10.1016\/j.ejpb.2021.07.014_b0760","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.addr.2019.06.003","article-title":"Nanomedicines - Tiny particles and big challenges","volume":"151\u2013152","author":"Marques","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2021.07.014_b0765","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1007\/s10620-012-2373-3","article-title":"Dietary Patterns and Self-Reported Associations of Diet with Symptoms of Inflammatory Bowel Disease","volume":"58","author":"Cohen","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejpb.2021.07.014_b0770","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2021.651415","article-title":"Novel and Emerging Therapies for Inflammatory Bowel Disease","volume":"12","author":"Al-Bawardy","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejpb.2021.07.014_b0775","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology."},{"key":"10.1016\/j.ejpb.2021.07.014_b0780","doi-asserted-by":"crossref","first-page":"S678","DOI":"10.1093\/ecco-jcc\/jjx107","article-title":"Targeting S1P in inflammatory bowel disease: New avenues for modulating intestinal leukocyte migration","volume":"12","author":"Danese","year":"2018","journal-title":"J. Crohn\u2019s Colitis."},{"key":"10.1016\/j.ejpb.2021.07.014_b0785","doi-asserted-by":"crossref","DOI":"10.1007\/s11894-020-0745-y","article-title":"First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician","volume":"22","author":"Chang","year":"2020","journal-title":"Curr. Gastroenterol. Rep."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641121002010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641121002010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:44:15Z","timestamp":1760546655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641121002010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":157,"alternative-id":["S0939641121002010"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2021.07.014","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mesalazine and inflammatory bowel disease \u2013 From well-established therapies to progress beyond the state of the art","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2021.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}